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within the human population, the tetanus toxoid-derived 
peptide TT830-844 was selected as a T-helper epitope 
because it can bind to various HLA-DRB molecules. We 
showed that the MAG-Tn3 vaccine, which was formu-
lated with the GSK proprietary immunostimulant AS15 
and designed for human cancer therapy, is able to induce 
an anti-Tn antibody response in mice of various H-2 haplo-
types, and this response correlates with the ability to induce 
a specific T cell response against the TT830-844 peptide. 
The universality of the TT830-844 peptide was extended 
to new H-2 and HLA-DRB molecules that were capable of 
binding this T cell epitope. Finally, the MAG-Tn3 vaccine 
was able to induce anti-Tn antibody responses in cynomol-
gus monkeys, which targeted Tn-expressing tumor cells 
and mediated tumor cell death both in vitro and in vivo. 
Thus, MAG-Tn3 is a highly promising anticancer vaccine 
that is currently under evaluation in a phase I clinical trial.
Keywords Universal epitope · TT830-844 · MAG-Tn3 · 
Antibody response · Anticancer vaccine
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Abstract Malignant transformations are often associ-
ated with aberrant glycosylation processes that lead to the 
expression of new carbohydrate antigens at the surface of 
tumor cells. Of these carbohydrate antigens, the Tn antigen 
is particularly highly expressed in many carcinomas, espe-
cially in breast carcinoma. We designed MAG-Tn3, a fully 
synthetic vaccine based on three consecutive Tn moieties 
that are O-linked to a CD4+ T cell epitope, to induce anti-
Tn antibody responses that could be helpful for therapeu-
tic vaccination against cancer. To ensure broad coverage 
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MAG  Multiple antigenic glycopeptide
ODN  Oligodeoxynucleotides
OWM  Old World monkeys
PV  Poliovirus
sc  Subcutaneous/subcutaneously
SFC  Spot-forming cells
TT  TT830-844 peptide
Introduction
Malignant transformations are often associated with a 
deregulation of glycosylation processes, which leads to the 
expression of tumor-associated carbohydrate antigens at 
the surface of tumor cells [1]. The Tn antigen, defined as an 
α-D-N-acetylgalactosamine (GalNAc) linked to a serine or 
threonine residue, is one of the most tumor-specific carbo-
hydrate antigens; it is expressed in approximately 90 % of 
carcinomas [2], including 80 % of breast cancer tissues [3]. 
These attributes make Tn an interesting target for the devel-
opment of anticancer vaccines.
Carbohydrate antigens are T-cell-independent antigens 
[4]. Because they are not able to induce an efficient anti-
body response by themselves, they need to be linked to 
appropriate carrier molecules. Therefore, we developed a 
dendrimeric multiple antigenic glycopeptide (MAG), based 
on a multivalent display of a Tn antigen trimer associated 
with a T-helper epitope, to induce a specific anti-Tn anti-
body response. We previously demonstrated the efficacy of 
the MAG strategy in mice using the poliovirus (PV) pep-
tide as a T-helper epitope. Indeed, the MAG-Tn3-PV con-
struct was able to induce high levels of anti-Tn antibodies 
in BALB/c mice and, more importantly, led to the survival 
of 80 % of mammary tumor-bearing mice (TA3Ha) after 
either prophylactic or therapeutic treatment [5, 6].
One major obstacle to vaccination in humans is the high 
degree of MHC polymorphism in the human population; 
more than 12,000 class I and class II MHC alleles have 
been reported so far [7]. However, broad coverage within 
the human population can potentially be achieved by using 
a promiscuous T-helper epitope, such as the tetanus toxoid-
derived P2 peptide TT830-844 (TT). TT has been described 
to be universally immunogenic in various species, includ-
ing mice [8–10] and humans [8, 11–15].
Thus, we designed a MAG-Tn3 vaccine for active 
immunotherapy in humans, using TT as a T-helper epitope 
(Sup. Fig. 1), and analyzed in the present study its capac-
ity to induce anti-tumor responses in preclinical models. 
We demonstrated its ability to induce high anti-Tn antibody 
levels in both mice and non-human primates. Furthermore, 
we confirmed and extended our knowledge about murine 
and human MHC II molecules that are able to bind TT. 
Finally, we demonstrated the anti-tumor potential of the 
anti-Tn antibodies induced in response to MAG-Tn3 vacci-
nation and showed their capacity to recognize and mediate 
killing of tumor cells in vitro and in vivo.
The present study thus established that the MAG-Tn3 
containing the TT epitope, produced under good manufac-
turing practices (GMP) condition and formulated in AS15, 
is able to induce anti-Tn antibodies with a high therapeu-
tic potential in various preclinical models. Based on these 
results, the MAG-Tn3/AS15 is currently under evaluation 
as a therapeutic vaccine for breast cancer patients, in a 
phase I clinical trial.
Materials and methods
Mice
HLA-DR1*A2 transgenic mice expressing human HLA-
DRB1*01:01, HLA-DRA*01:01 and HLA-A*02:01 [16] 
were from the Pasteur Institute animal colony. Six-week-
old female C57BL/6J, BALB/c, C3H/HeN, NMRI and 
CD-1 mice were purchased from Charles River Laborato-
ries. Mice were kept in the Pasteur Institute animal house 
and supplied with water and food ad libitum. All proce-
dures involving mice were in accordance with the French 
Ethical Committee CETEA (comité d’éthique en expéri-
mentation animale) (Project No. 2013-126).
Non‑human primates
Cynomolgus monkeys (20 per gender) were bred and 
quarantined at Le Tamarinier (Tamarin, Mauritius) before 
being shipped to CiToxLAB France at 27–32 months old. 
Primates were acclimated to the study conditions for a 
period of 15 days before beginning treatment. All animals 
had free access to tap water, and food was distributed daily. 
The study was performed in compliance with CiToxLAB 
France’s standard operating procedures and the principles 
of Good Laboratory Practice, and the study was in compli-
ance with Animal Health regulations.
Cells and reagents
The Tn-expressing Jurkat cell line transfected with GFP 
(Jurkat-GFP) [17], mammary carcinoma cell line MCF-7 
[18], ovarian carcinoma cell lines OVCAR [19] and SHIN3 
[20], and the murine mammary carcinoma TA3Ha cell line 
[21] were cultured in complete RPMI 1640 medium (Invit-
rogen) supplemented with 10 % FCS (Hyclone) and antibi-
otics (100 U/mL penicillin and 100 μg/mL streptomycin, 
Invitrogen).
The MAG-Tn3 vaccine was produced by Lonza as pre-
viously described [22]. AS15 is a combination of AS01B 
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and CpG 7909 synthetic oligodeoxynucleotides (ODNs) 
containing unmethylated CpG motifs in a liposomal for-
mulation [23]. The MAG-Tn3/AS15 formulation con-
sisted of lyophilized MAG-Tn3 (300 μg) combined with 
CpG (420 µg) and reconstituted with the AS01B adjuvant 
(500 μL) at the time of administration.
Complete and incomplete Freund’s adjuvants (respec-
tively, CFA and IFA) were purchased from Sigma-Aldrich. 
The tetanus toxoid TT830-844 peptide (QYIKANSKFI-
GITEL) and the H-2k-restricted HEL45-61 peptide derived 
from hen egg lysozyme (RNTDGSTDYGILQINSR) [24] 
were obtained from Polypeptide.
The anti-CD4 (GK1.5) monoclonal antibody (mAb) was 
prepared from ascitic fluid [25]. The anti-rat IgG2b isotype 
control (LTF2) was purchased from BioXCell. The IgG2b 
murine anti-Tn mAb 8D4 was obtained from BALB/c mice 
immunized with MAG-Tn3-PV, as previously described 
[3]. The Herceptin mAb (trastuzumab, anti-Her2) was pur-
chased from Hoffmann-La Roche. The chimeric Chi-Tn 
mAb was produced as previously described [26].
Immunization
For the vaccination experiment, mice were intramuscularly 
(im) immunized with either 1/20, 1/7 or 1/5 of MAG-Tn3 
formulated with AS15, which corresponds to 15, 45 or 
60 μg of MAG-Tn3. Immunizations were performed 3–5 
times at 3-week intervals.
For the T cell depletion experiment, mice vaccinated on 
days 0 and 21 were intraperitoneally (ip) treated with anti-
CD4 or isotype control antibody (300 μg) on days −1, 0, 1, 
20, 21 and 22.
For the peptide presentation experiment, mice were sub-
cutaneously (sc) immunized with 50 μg of either TT or 
HEL formulated in CFA. In some experiments, a second 
injection was performed at day 11 with peptide formulated 
in IFA.
Cynomolgus monkeys were immunized with NaCl or 
AS15 alone (sc) or 300 μg of MAG-Tn3 formulated with 
the AS15 immunostimulant (sc or im). Immunizations were 
performed 7 times at 3-week intervals.
Measurement of Tn‑specific antibody response 
by ELISA and flow cytometry
Sera from immunized mice and monkeys were tested for 
the presence of anti-Tn antibodies by ELISA, using neutra-
vidin pre-coated plates (Thermo Scientific) coated with the 
synthetic biotinylated Tn3-G6K(Biot)G glycopeptide [6]. 
The detection antibodies anti-mouse-IgM-HRP and anti-
mouse-IgG-HRP or anti-human-IgM-HRP and anti-human-
IgG-HRP (Sigma-Aldrich) were used. The antibody titers 
were calculated as previously described [5].
Cynomolgus sera were also tested for their ability to 
bind to the Tn-expressing human cell lines using goat anti-
human-IgM-FITC and IgG-PE (Southern Biotech). Anti-
body titers were calculated as previously described [6].
Measurement of T cell response by intracellular 
staining
Mouse cell suspensions were stimulated with 50 μg/mL 
of TT or HEL peptide in the presence of BD GolgiPlug™ 
(BD Biosciences) for 2 h (37 °C). Cells were fixed and 
stained using the BD Cytofix/Cytoperm™ Kit (BD Bio-
sciences). Surface and intracellular staining (ICS) were 
performed according to the manufacturer’s instructions, 
with anti-CD4-FITC, anti-CD3-APC-eFluor®780, anti-
CD19-PECy7, anti-TNF-α-PerCP-e710, anti-IL-2-APC 
and anti-IFNγ-EF450 from eBioscience and anti-CD8a-PE 
from BD Biosciences.
Measurement of T cell response by ELISA 
and ELISPOT
The murine T cell response was analyzed by ELISA, using 
antibodies against IFN-γ and IL-5 (BD Biosciences), 
IL-13 and IL-17 (R&D System). Measurements were per-
formed on culture supernatants of mouse cell suspensions 
stimulated with or without 50 μg/mL of TT for 48–72 h. 
The cynomolgus IFN-γ response was analyzed on PBMC 
stimulated for 48 h with 50 μg/mL of TT using the mon-
key IFN-γ ELISpotBASIC (ALP) kit from Mabtech, accord-
ing to the manufacturer’s instructions. Spot-forming cells 
(SFC) were counted using the ELISPOT reader Bioreader® 
5000 E-β (Biosys). All measurements were performed in 
triplicate.
Complement‑dependent cytotoxicity assay
The complement-dependent cytotoxicity assay (CDC) was 
performed with IgG purified from pre-immunized (day 1) 
and post-immunized (day 126) sera of cynomolgus mon-
keys using Zeba™ Spin Desalting Columns (Thermo Sci-
entific) and the Melon Gel IgG Purification Kit (Thermo 
Scientific). CDC activity was evaluated in Jurkat-GFP 
cells and MCF-7, SHIN3 and OVCAR cells labeled with 
5 μM of CFSE (carboxyfluorescein succinimidyl ester, 
Life Technologies). Cells (6000/well) were incubated 
with cynomolgus antibodies at various concentrations and 
DRAQ7 viability dye (Abcam) at 2 μM, in the presence 
or absence of 1 % of rabbit complement-MA (Cedarlane) 
for 2 h in 384-well plates (37 °C). Green fluorescence (live 
cells) and red (dead cells) fluorescence were measured on 
an Incucyte™ ZOOM instrument (Essen Bioscience), and 
the number of cells was calculated using ZOOM software 
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(Essen Bioscience). All measurements were performed in 
duplicate. The percentage of CDC was determined as fol-
lows: % of CDC = ((% of dead cells)complement – (% of 
dead cells)medium) normalized against the control without 
antibody.
In vivo tumor immunotherapy
Mice were injected ip on day 0 with 103 TA3Ha tumor 
cells. The day after the graft (day 1), mice were injected 
ip with cyclophosphamide (CTX) at 50 mg/kg. Starting 
from day 2 after the graft, mice were treated twice a week 
with 8D4, the Chi-Tn anti-Tn mAb [26] or Herceptin (tras-
tuzumab) at 20 mg/kg ip (six total injections). Mouse sur-
vival was monitored over a 1.5-month period.
HLA binding assay
The binding kinetics of TT for 24 human HLA-DRB 
molecules were measured using the REVEAL®MHC 
binding assay (ProImmune; www.proimmune.com). 
Detection of bound peptide was based on the presence 
or absence of the native conformation of the HLA–pep-
tide complex, which is detected by a specific monoclo-
nal antibody. The score of the test peptide is reported 
quantitatively as a percentage of the signal generated by 
the positive control peptide. Scores >14 were considered 
positive for binding.
Statistical analysis
Statistical analyses were performed using parametric Stu-
dent’s t tests (GraphPad Software). P values <0.05 were 
considered statistically significant. Kaplan–Meier survival 
curves were created using the log-rank test on GraphPad 
Software.
Results
Immunogenicity of the MAG‑Tn3 vaccine in mice 
with different H‑2 haplotypes
To ensure broad coverage of the MAG-Tn3 vaccine within 
the human population, we selected the universal TT830-
844 peptide (TT) as a T-helper epitope. The AS15 immu-
nostimulant, already accepted for human use [27], was 
selected for clinical evaluation based on its ability to 
induce high anti-Tn antibody titers in HLA-DR1*A2 mice 
expressing the human HLA-DRB1*01:01 allele, known to 
bind TT [8, 11, 13, 28, 29] (Sup. Fig. 2). The clinical for-
mulation of MAG-Tn3 with the AS15 immunostimulant, 
produced under GMP conditions, was evaluated in mice.
The immunogenicity of MAG-Tn3 formulated with 
AS15 was first tested on HLA-DR1*A2 mice, and simi-
lar anti-Tn IgG titers were observed at the three MAG-
Tn3 doses tested (Fig. 1a). The lowest dose (15 μg) was 
selected for further experimentation.
The immunogenicity of the MAG-Tn3/AS15 formula-
tion was tested in several inbred mouse strains, C3H/HeN 
(H-2k), C57BL/6 J (H-2b) and BALB/c (H-2d) and out-
bred NMRI and CD-1 mice. Following three immuniza-
tions, no anti-Tn IgG production was detected in C57BL/6J 
and BALB/c sera, while C3H/HeN and both outbred mice 
NMRI and CD-1 produced high amounts of anti-Tn IgG 
(Fig. 1b), demonstrating the ability of the TT peptide to 
help the production of anti-Tn antibodies in mice express-
ing various H-2 haplotypes.
We then evaluated the T cell response to TT after MAG-
Tn3 vaccination by measuring the production of TH1, TH2 
and TH17 cytokines in response to in vitro stimulation 
with TT (Fig. 1c). Because the binding of TT to the H-2d 
molecule has been previously described [9, 10], we also 
evaluated the T cell response induced in BALB/c mice. 
No cytokine production was detected for BALB/c mice, 
whereas IFN-γ was found to be the main cytokine pro-
duced in response to TT in all other strains of mice. An 
IL-17 response was also observed in C3H/HeN, and IL-17, 
IL-5 and IL-13 were detected in NMRI and CD-1. The anti-
Tn antibody production induced in response to MAG-Tn3 
vaccination is therefore associated with a T cell response to 
TT, mainly oriented toward a TH1 profile.
We previously demonstrated that in the absence of a 
T-helper epitope, MAG-Tn3 is not able to induce anti-Tn 
antibody production in mice [30]. To confirm the CD4+ 
T cell dependency of the anti-Tn antibody response, we 
measured the immunogenicity of the MAG-Tn3 vaccine 
with AS15 in C3H/HeN mice depleted of CD4+ T cells. As 
shown in Fig. 2a, b, no CD4+ T cells were detectable in the 
blood of anti-CD4-treated mice harvested at day 21, con-
firming the complete depletion of CD4+ T cells at the time 
of vaccination. As expected, no anti-Tn IgG production 
was induced in these mice, whereas untreated mice or mice 
treated with the control isotype produced high amounts of 
anti-Tn IgG (Fig. 2c), confirming the CD4+ T cell require-
ment for anti-Tn antibody production by B cells.
Immunogenicity of TT in mice of different H‑2 
haplotypes
We demonstrated the ability of TT to induce a T cell 
response to the MAG-Tn3 vaccine in mice expressing vari-
ous H-2 haplotypes. To confirm the promiscuity of TT in 
mice, both inbred (C3H/HeN, C57BL/6J and BALB/c) and 
outbred (NMRI and CD-1) mice were directly immunized 
with TT in CFA, and cytokine production was measured by 
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ICS and ELISA. HLA-DR1*A2 mice were used as a posi-
tive control.
Following immunization with either TT or HEL, CD4+ 
T cells from C3H/HeN lymph nodes were able to produce 
TNF-α, IL-2 and IFN-γ in response to in vitro TT or HEL 
stimulation, showing the specificity of the T cell response 
(Fig. 3a–c, Sup. Fig. 3a).
In correlation with the T cell response observed follow-
ing MAG-Tn3 vaccination (Fig. 1), the highest cytokine 
response to TT was observed for the outbred mice immu-
nized with TT, while a lower response was measured 
for HLA-DR1*A2, and no response was detected for 
C57BL/6J mice (Fig. 3d–f, Sup. Fig. 3b). In these condi-
tions, we were able to detect a T cell response to TT in 
BALB/c splenocytes, though it was lower than for HLA-
DR1*A2 and outbred strains.
Characterization of HLA‑DRB molecules able 
to present TT
TT was initially defined as a promiscuous peptide due to 
its ability to induce the proliferation of human PBMCs 
expressing different HLA-DRB molecules [11–14, 28, 
31], but its universal immunogenicity has recently been 
Fig. 1  Immunizing mice of different H-2 haplotypes with MAG-Tn3 
induce a specific anti-Tn IgG response associated with a TT-specific 
T cell response. a HLA-DR1*A2 transgenic mice were im immu-
nized on days 0, 21, 42, 63 and 84 with 15 (n = 12), 45 (n = 12) 
or 60 μg (n = 10) of MAG-Tn3 with 1/20, 1/7 and 1/5 of the AS15 
immunostimulant, respectively, or with the AS01B immunostimulant 
alone. b C57BL/6J, C3H/HeN, BALB/c mice (n = 6) and NMRI and 
CD-1 mice (n = 8) were im immunized on days 0, 21 and 42 with 
15 μg of MAG-Tn3 with 1/20 of the AS15 immunostimulant (mid-
dle and right panels), or with the AS01B immunostimulant alone (left 
panel). Sera were collected on days 21, 28 and 49 and tested for Tn-
specific IgG by ELISA using Tn3-G6K (Biot) G. Antibody titers are 
expressed as the mean of Log10 individual antibody titers ± SEM. 
c. IFN-γ, IL-5, IL-13 and IL-17 production was analyzed by ELISA 
on supernatants of splenocytes stimulated with (black bars) or with-
out (white bars) 50 μg/mL of TT for 72 h. The results are expressed 
as the means of individual mice ± SEM. The statistical significance 
of differences was determined by the Student t test (*P < 0.05, 
**P < 0.01). ND not detectable
320 Cancer Immunol Immunother (2016) 65:315–325
1 3
the subject of controversy [29, 32]. To have a more global 
view of TT immunogenicity in humans, we performed 
an HLA binding assay on HLA-DRB molecules corre-
sponding to 24 human HLA-DRB alleles. We identified 
9 HLA-DRBs capable of binding TT, with 100 % bind-
ing to HLA-DRB1*01:01, DRB1*04:05, DRB1*07:01, 
DRB1*11:01 and DRB5*01:01 (Fig. 4a). TT can be rec-
ognized by some of the most frequently expressed alleles, 
such as DR1*07:01, which is present in almost 15 % of 
all ethnic populations except Chinese, or DRB1*01:01 
and DRB1*04:01, which are expressed by 6–8 % of North 
Americans and Europeans (Fig. 4b).
Immunogenicity of the MAG‑Tn3 vaccine 
in cynomolgus monkeys
Finally, we evaluated MAG-Tn3 immunogenicity in a pre-
clinical model of cynomolgus monkeys, which are more 
closely related to humans, using either sc or im routes of 
immunization. As shown in Fig. 5a, both anti-Tn IgM and 
IgG responses were detected in all animals immunized with 
the MAG-Tn3 vaccine, even after one immunization. This 
antibody response was associated with a T cell response to TT 
because cynomolgus PBMCs stimulated with TT were able to 
produce IFN-γ (Fig. 5b, c). No differences in immunogenic-
ity were observed between the two routes of immunization.
We then determined the biological activity of the anti-Tn 
antibodies produced in cynomolgus monkeys. In Fig. 6a, 
we showed that both anti-Tn IgM and IgG were able to rec-
ognize the human T-lymphoma Jurkat cells by FACS, and 
the anti-Tn antibody titers correlated with those determined 
by ELISA (Fig. 5a). We also observed recognition of the 
mammary carcinoma cell line MCF7 and the ovarian car-
cinoma cell lines SHIN3 and OVCAR (Fig. 6b and Sup. 
Fig. 4) to a lesser extent.
Because anti-Tn antibodies are able to target Tn-express-
ing tumor cells, we determined their ability to mediate kill-
ing of these cells through CDC activity (Fig. 6c, d). Sera 
of cynomolgus monkeys immunized with MAG-Tn3 were 
able to mediate CDC in Jurkat and SHIN3 cells, with no 
significant difference between the routes of immunization. 
Under these conditions, no killing of MCF7 and OVCAR 
cells was observed. No killing of Tn-expressing cells was 
observed with the sera of the NaCl or AS15 immunostim-
ulant control groups (Fig. 6d). The CDC activity of cyn-
omolgus antibodies was detectable at lower doses in Jurkat 
cells compared with SHIN3 cells (Sup. Fig. 5).
Finally, we analyzed the ability of anti-Tn antibodies to 
inhibit tumor growth in vivo by using the 8D4 murine mAb 
produced from MAG-Tn3-PV-treated mice, as previously 
described [3]. BALB/c mice grafted with the Tn-expressing 
TA3Ha murine breast cancer cells were treated with the 
8D4 mAb, the chimeric mAb Chi-Tn [26], or with the irrel-
evant mAb Herceptin, in association with CTX treatment 
(Fig. 6e).
As previously described, treatment with the Chi-Tn mAb 
allowed 70 % of mice to survive [26], while mice treated 
with Herceptin had only 20 % survival. The mice treated 
with the 8D4 anti-Tn mAb displayed a survival percentage 
similar to mice treated with the Chi-Tn, demonstrating the 
protective capacity of the anti-Tn antibodies produced in 
response to MAG-Tn3 vaccination.
Discussion
In the present study, we demonstrate that the MAG-Tn3 
vaccine formulated with the AS15 immunostimulant is 
able to induce a high level of anti-Tn antibody production 
in both mice and cynomolgus monkeys, establishing the 
potential of the universal TT peptide as a T-helper epitope 
for the induction of anti-tumor immune responses against 
the Tn carcinoma antigen.
Fig. 2  The anti-Tn IgG response induced by the MAG-Tn3 vaccine 
is CD4+ T cell dependent. a, b C3H/HeN mice (n = 6/group) that 
were left untreated or treated with anti-CD4 or isotype control anti-
bodies (300 μg ip) on days −1, 0, 1, 20, 21 and 22 were im immu-
nized on days 0 and 21 with 15 μg of MAG-Tn3 with 1/20 of the 
AS15 immunostimulant. CD4+ T cell depletion was confirmed by 
FACS analysis of the percentages of CD4+ and CD8+ cells among 
CD3+ cells on blood samples collected on day 21, prior to vaccina-
tion. Dot plots of one representative mouse per group are shown (a). 
The results are expressed as the mean of individual mice ± SEM 
(b). c Sera were collected on days 21 and 28 and tested for Tn-spe-
cific IgG by ELISA, using Tn3-G6K (Biot) G. Antibody titers are 
expressed as the mean of Log10 individual antibody titers ± SEM. 
The statistical significance of differences was determined by the Stu-
dent t test (**P < 0.01)
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The MAG-Tn3 vaccine formulated in AS15 immu-
nostimulant induced a strong anti-Tn IgG response in HLA-
DR1*A2 transgenic mice, in C3H/HeN inbred mice and 
in two outbred strains of mice. This was associated with 
a T cell response oriented toward a TH1 profile and IFN-γ 
cytokine production, confirming that these mice were able 
to generate a CD4+ T cell response upon vaccination with 
MAG-Tn3, which helps B cells produce anti-Tn antibodies.
The ability to bind and present the TT peptide was con-
firmed through direct immunization assays. The T cell 
response intensity to direct TT immunization was cor-
related with the level of the anti-Tn antibody response to 
MAG-Tn3 in outbred and HLA-DR1*A2 mice. Interest-
ingly, while C3H/HeN mice displayed high anti-Tn anti-
body response to MAG-Tn3, a weak T cell response to 
direct TT immunization was detected on lymph nodes. 
In addition, while BALB/c mice were able to respond to 
immunization with the TT peptide in CFA, confirming pre-
vious reports [8–10], no TT-specific T cell response nor 
anti-Tn antibody production was observed in these mice 
in response to vaccination by MAG-Tn3 in AS15. Thus, 
although the TT peptide can stimulate T cell responses 
in BALB/c mice in the presence of a strong adjuvant, its 
immunogenicity could not be sufficient to provide T cell 
help for anti-Tn antibody production after immunization 
with MAG-Tn3 in AS15.
Our results extended our knowledge on TT immuno-
genicity in mice because it can be presented by two outbred 
strains of mice, both belonging to the Swiss mouse fam-
ily [33]. However, while these mice are currently randomly 
bred and thus constitute a heterogeneous population, their 
genetic heterogeneity depends on the stock history [33]. 
Costagliola et al. [34] determined that approximately 90 % 
of the NMRI mice used for their studies express the H-2q 
haplotype, indicating reduced polymorphism for this strain. 
In contrast, Elia et al. [35] characterized greater polymor-
phism in a population of 30 CD-1 mice, in which mice 
expressed q/q (23 %), q/j (33 %), q/b (17 %), b/k (10 %) or 
j/j (17 %) haplotypes. Together, these data indicate that TT 
can be presented by H-2q and H-2j haplotypes.
TT was first described as a universal peptide based on 
its ability to be recognized by human PBMC expressing 
Fig. 3  The TT epitope can be 
recognized and presented by 
different murine MHC class II 
and human HLA-DRB1*01:01 
molecules. a–c. C3H/HeN mice 
(n = 5) were sc immunized with 
50 μg of TT or HEL with CFA. 
On day 11, TNF-α produc-
tion was analyzed by ICS on 
individual lymph nodes (a) and 
IFN-γ (b) and IL-2 (c) produc-
tion was analyzed by ELISA on 
pooled lymph nodes stimu-
lated with TT (black bars) or 
HEL (white bars). The results 
are expressed as the mean of 
individual mice ± SEM. d, 
e, f. HLA-DR1*A2 (n = 3), 
C57BL/6J (n = 3), BALB/c 
(n = 3), NMRI (n = 3) and 
CD-1 (n = 6) mice were sc 
immunized with 50 μg of TT 
or with immunostimulant alone 
on days 0 and 14. On day 28, 
TNF-α production was analyzed 
by ICS (d) and IFN-γ (e) and 
IL-2 (f) production was ana-
lyzed by ELISA on splenocytes 
stimulated with TT (black bars) 
or HEL (white bars). The results 
are expressed as the mean of 
triplicates ± SEM. The statisti-
cal significance of differences 
was determined by the Student t 
test (*P < 0.05, **P < 0.01)
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various HLA-DRB molecules, and to date, at least 10 dif-
ferent class II molecules have been described to be capa-
ble of interacting with TT [8, 12, 13, 15, 28, 29, 32]. How-
ever, these studies were performed using different types 
of assays. To have a more homogeneous analysis of TT 
immunogenicity in humans, we evaluated the ability of 
HLA-DRB molecules of 24 HLA-DRB alleles to bind this 
peptide using an HLA binding assay. We selected alleles of 
the three functional genes DRB1, DRB3 and DRB5 [36]. 
We mainly focused on DRB1 alleles because the DRB1 
gene has the most polymorphisms; 1825 alleles have been 
reported so far [7]. The DRB1 allelic lineage is divided 
across five haplogroups: HLA-DRB1*01 and *10 (DR1), 
*08 (DR8), *15 and *16 (DR51), *03, *11, *13 and *14 
(DR52) and finally *04, *07 and *09 (DR53) [37, 38]. 
We therefore selected the HLA-DRB1 alleles of various 
haplogroups.
We measured binding of TT by HLA-DRB1*01:01, 
DRB1*04:01, DRB1*11:01 and DRB3*03:01 and con-
firmed previous results [11–13, 28, 29, 32, 39]. We also 
confirmed the absence of binding by HLA-DRB1*15:01 
[29]. However, in contrast to earlier studies, we were not 
able to detect the binding of TT by HLA-DRB1*03:01 
and HLA-DRB1*11:02 [11, 12, 15, 32]. Finally, we char-
acterized new HLA-DRB molecules that could bind 
TT: HLA-DRB1*04:05, DRB1*04:08, DRB1*07:01, 
DRB1*09:01 and DRB5*01:01. These results indicate that 
TT can bind to DRB1 molecules representative of four hap-
logroups (DRB1, DR51, DR52 and DR53).
MAG-Tn3/AS15 immunogenicity was finally evalu-
ated in cynomolgus monkeys, which share with humans 
many similarities in their MHC II region. Indeed, similar 
to humans, the MHC II molecules of Old World monkeys 
(OWM), such as cynomolgus monkeys, are composed of 
multiple DRB regions [40, 41], with the presence of DRB1, 
DRB3 and DRB5 genes [42]. We previously showed that 
the MAG-Tn3 vaccine formulated in alum is able to induce 
an anti-Tn antibody response in African green and rhesus 
OWM species [30]. Here, we showed that the MAG-Tn3 
vaccine formulated with the AS15 immunostimulant is able 
to induce anti-Tn antibody responses associated with an 
IFN-γ T cell response to TT in cynomolgus monkeys, and 
Fig. 4  TT can be presented by different human HLA-DRB mol-
ecules. a The HLA binding assay was performed using TT against 
human HLA-DRB molecules of various HLA-DRB alleles. b The fre-
quency of HLA-DRB molecules capable of binding TT is given for 
various populations, based on data published at www.allelefrequen-
cies.net. NDA no data available
Fig. 5  Immunization of cynomolgus monkeys with the MAG-Tn3 
vaccine induces a specific anti-Tn antibody response associated with 
a T cell response to TT. Cynomolgus monkeys (n = 10/group) were 
immunized on days 0, 21, 42, 63, 84 and 105 with NaCl, AS15 or 
MAG-Tn3 formulated with AS15. a Sera were collected on the 
day of each immunization and tested for Tn-specific IgM and IgG 
responses by ELISA. b, c T cell responses were measured on cyn-
omolgus PBMCs harvested after five immunizations (day 105), 
stimulated with (black bars) or without TT (white bars). IFN-γ pro-
duction was evaluated by ELISPOT and is expressed as the mean of 
individual SFC per 106 cells ± SEM (b). Pictures are shown of one 
representative well per group, seeded with 106 cells (c). The statisti-
cal significance of differences was determined by the Student t test 
(**P < 0.01)
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no adverse reactions were observed during the study (data 
not shown).
We showed that at least three different OWM species 
are able to respond to this peptide, reinforcing the univer-
sal nature of TT. However, it should be noted that, although 
OWM and humans have similarities in MHC class II, the 
DRB region of OWM is more complex, with both higher 
numbers and combinations of DRB genes than in humans, 
leading to the expression of more than 30 haplotypes [40, 
41, 43, 44]. Moreover, some genes, named DRW genes, are 
specific to OWM, and configurations without DRB1 are 
found in OWM [44]. Finally, the allelic polymorphism of 
DRB1 genes seems to be limited compared with humans 
[36, 42].
This study also demonstrated the anti-tumor activity of 
the anti-Tn antibodies induced in response to MAG-Tn3 
vaccination. Similar to other previously described anti-Tn 
antibodies, such as the therapeutic mAb MLS128 [45], 
these antibodies were able to recognize various Tn-express-
ing tumor cells, such as Jurkat and MCF7 tumor cell lines. 
The anti-tumor therapeutic potential of the antibodies elic-
ited in cynomolgus monkeys was shown by their in vitro 
Fig. 6  Anti-Tn antibodies are able to induce the death of Tn-express-
ing tumor cells in vitro and in vivo. a, b. Pre- and post-immunized 
sera, obtained from cynomolgus monkeys (n = 10/group) after 
the immunization protocol described in Fig. 5, were analyzed for 
their ability to recognize Tn-expressing tumor cells. The binding 
of sera to Jurkat cells was revealed using double labeling with anti-
human-IgM-PE and anti-human-IgG-FITC (a). Sera of cynomolgus 
monkeys vaccinated with MAG-Tn3 were collected at day 105 and 
tested for Tn-specific binding to different Tn-expressing tumor cells, 
compared with naive sera (b). Antibody titers are expressed as the 
mean of Log10 individual antibody titers ± SEM. c, d CDC activ-
ity of pre-immunized (day 1) and post-immunized (day 126) sera of 
cynomolgus monkeys was analyzed on various Tn-expressing cells. 
Representative pictures of green and red fluorescence and associated 
transmission images for CDC on Jurkat-GFP cells are shown (c). The 
results are expressed as the mean of individual % of CDC ± SEM 
(d). e BALB/c mice grafted with TA3Ha cells were injected with 
CTX (50 mg/kg, day 1 after graft) and then treated (six injections) 
with the 8D4 murine anti-Tn mAb (n = 8), the Chi-Tn mAb (n = 8) 
or the Herceptin mAb (n = 6), and mouse survival was followed for 
48 days. The statistical significance of differences was determined by 
the Student t test (*P < 0.05; **P < 0.01)
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capacity to mediate the killing of Jurkat cells and SHIN3 
ovarian carcinoma cells in the presence of complement. 
No killing of mammary MCF7 and ovarian OVCAR cell 
lines by CDC mechanism was observed. However, antibod-
ies specific for tumor-associated antigens can also mediate 
tumor cell killing through the antibody-dependent cytotox-
icity (ADCC) mechanism. Indeed, we previously showed 
that anti-Tn antibodies produced in rhesus monkeys in 
response to MAG-Tn3 formulated in alum were able to 
mediate the killing of Jurkat cells in the presence of human 
NK cells [30]. Finally, the 8D4 murine anti-Tn mAb, in 
combination with CTX treatment, allowed for the survival 
of 70 % of TA3Ha tumor-bearing mice, demonstrating the 
therapeutic potential of anti-Tn antibodies in vivo.
In conclusion, this preclinical study confirmed the 
strong potential of the MAG-Tn3 vaccine formulated with 
AS15 for the induction of functional antibody responses 
against the tumor-specific Tn antigen. This vaccine candi-
date is currently under evaluation in a phase I clinical trial 
in breast cancer patients.
Acknowledgments The work was funded by the Ligue Nationale 
Contre le Cancer (Equipe Labellisée 2014), the Banque Privée Euro-
péenne, the European Union’s Seventh Framework Programme under 
Grant Agreement No: 280873 ADITEC and the donors of the MAG-
Tn3 program. The authors thank the PIRC (Pôle Integré de Recherche 
Clinique, Institut Pasteur, Paris, France) for their help in the organi-
zation of experiments on cynomolgus monkeys. The authors thank 
Nancy Dezutter, Valentine Wascotte and David Bouffard for develop-
ing the MAG-Tn3 formulation and for discussions.
Compliance with ethical standards 
Conflict of interest Anne-Laure Puaux and Catherine Gérard are 
employed by the GSK group of companies. Catherine Gérard declares 
stock ownership in the GSK group of companies, and Anne-Laure 
Puaux declares annual stock options. All other authors declare that 
they have no conflicts of interest.
Open Access This article is distributed under the terms of the 
Creative Commons Attribution 4.0 International License (http://crea-
tivecommons.org/licenses/by/4.0/), which permits unrestricted use, 
distribution, and reproduction in any medium, provided you give 
appropriate credit to the original author(s) and the source, provide a 
link to the Creative Commons license, and indicate if changes were 
made.
References
 1. Slovin SF, Keding SJ, Ragupathi G (2005) Carbohydrate 
vaccines as immunotherapy for cancer. Immunol Cell Biol 
83(4):418–428. doi:10.1111/j.1440-1711.2005.01350.x
 2. Springer GF (1997) Immunoreactive T and Tn epitopes in 
cancer diagnosis, prognosis, and immunotherapy. J Mol Med 
75(8):594–602
 3. Mazal D, Lo-Man R, Bay S, Pritsch O, Deriaud E, Ganneau C, 
Medeiros A, Ubillos L, Obal G, Berois N, Bollati-Fogolin M, 
Leclerc C, Osinaga E (2013) Monoclonal antibodies toward 
different Tn-amino acid backbones display distinct recogni-
tion patterns on human cancer cells. Implications for effec-
tive immuno-targeting of cancer. Cancer Immunol Immunother 
62(6):1107–1122. doi:10.1007/s00262-013-1425-7
 4. Mond JJ, Lees A, Snapper CM (1995) T cell-independent anti-
gens type 2. Annu Rev Immunol 13:655–692. doi:10.1146/
annurev.iy.13.040195.003255
 5. Lo-Man R, Bay S, Vichier-Guerre S, Deriaud E, Cantacuzene 
D, Leclerc C (1999) A fully synthetic immunogen carrying a 
carcinoma-associated carbohydrate for active specific immuno-
therapy. Cancer Res 59(7):1520–1524
 6. Lo-Man R, Vichier-Guerre S, Bay S, Deriaud E, Cantacuzene D, 
Leclerc C (2001) Anti-tumor immunity provided by a synthetic 
multiple antigenic glycopeptide displaying a tri-Tn glycotope. J 
Immunol 166(4):2849–2854
 7. Robinson J, Halliwell JA, McWilliam H, Lopez R, Parham P, 
Marsh SG (2013) The IMGT/HLA database. Nucleic Acids Res 
41(Database Issue):D1222–D1227. doi:10.1093/nar/gks949
 8. Alexander J, Sidney J, Southwood S, Ruppert J, Oseroff C, Mae-
wal A, Snoke K, Serra HM, Kubo RT, Sette A et al (1994) Devel-
opment of high potency universal DR-restricted helper epitopes 
by modification of high affinity DR-blocking peptides. Immunity 
1(9):751–761
 9. Valmori D, Pessi A, Bianchi E, Corradin G (1992) Use of human 
universally antigenic tetanus toxin T cell epitopes as carriers for 
human vaccination. J Immunol 149(2):717–721
 10. Joshi SK, Suresh PR, Chauhan VS (2001) Flexibility in MHC 
and TCR recognition: degenerate specificity at the T cell level 
in the recognition of promiscuous Th epitopes exhibiting no pri-
mary sequence homology. J Immunol 166(11):6693–6703
 11. Panina-Bordignon P, Tan A, Termijtelen A, Demotz S, Corra-
din G, Lanzavecchia A (1989) Universally immunogenic T cell 
epitopes: promiscuous binding to human MHC class II and pro-
miscuous recognition by T cells. Eur J Immunol 19(12):2237–
2242. doi:10.1002/eji.1830191209
 12. Boitel B, Ermonval M, Panina-Bordignon P, Mariuzza RA, Lan-
zavecchia A, Acuto O (1992) Preferential V beta gene usage and 
lack of junctional sequence conservation among human T cell 
receptors specific for a tetanus toxin-derived peptide: evidence 
for a dominant role of a germline-encoded V region in anti-
gen/major histocompatibility complex recognition. J Exp Med 
175(3):765–777
 13. O’Sullivan D, Arrhenius T, Sidney J, Del Guercio MF, Albertson 
M, Wall M, Oseroff C, Southwood S, Colon SM, Gaeta FC et al 
(1991) On the interaction of promiscuous antigenic peptides with 
different DR alleles. Identification of common structural motifs. 
J Immunol 147(8):2663–2669
 14. O’Sullivan D, Sidney J, Appella E, Walker L, Phillips L, Colon 
SM, Miles C, Chesnut RW, Sette A (1990) Characterization 
of the specificity of peptide binding to four DR haplotypes. J 
Immunol 145(6):1799–1808
 15. Blank U, Boitel B, Mege D, Ermonval M, Acuto O (1993) Anal-
ysis of tetanus toxin peptide/DR recognition by human T cell 
receptors reconstituted into a murine T cell hybridoma. Eur J 
Immunol 23(12):3057–3065. doi:10.1002/eji.1830231203
 16. Pajot A, Michel ML, Fazilleau N, Pancre V, Auriault C, Ojcius 
DM, Lemonnier FA, Lone YC (2004) A mouse model of 
human adaptive immune functions: HLA-A2.1-/HLA-DR1-
transgenic H-2 class I-/class II-knockout mice. Eur J Immunol 
34(11):3060–3069. doi:10.1002/eji.200425463
 17. Nakada H, Inoue M, Tanaka N, Numata Y, Kitagawa H, Fukui S, 
Yamashina I (1991) Expression of the Tn antigen on T-lymphoid 
cell line Jurkat. Biochem Biophys Res Commun 179(2):762–767
 18. Soule HD, Vazguez J, Long A, Albert S, Brennan M (1973) A 
human cell line from a pleural effusion derived from a breast car-
cinoma. J Natl Cancer Inst 51(5):1409–1416
325Cancer Immunol Immunother (2016) 65:315–325 
1 3
 19. Hamilton TC, Young RC, McKoy WM, Grotzinger KR, Green 
JA, Chu EW, Whang-Peng J, Rogan AM, Green WR, Ozols RF 
(1983) Characterization of a human ovarian carcinoma cell line 
(NIH:OVCAR-3) with androgen and estrogen receptors. Cancer 
Res 43(11):5379–5389
 20. Imai S, Kiyozuka Y, Maeda H, Noda T, Hosick HL (1990) Estab-
lishment and characterization of a human ovarian serous cystad-
enocarcinoma cell line that produces the tumor markers CA-125 
and tissue polypeptide antigen. Oncology 47(2):177–184
 21. Hauschka TS, Weiss L, Holdridge BA, Cudney TL, Zumpft M, 
Planinsek JA (1971) Karyotypic and surface features of murine 
TA3 carcinoma cells during immunoselection in mice and rats. J 
Natl Cancer Inst 47(2):343–359
 22. Bay S, Leclerc C, Lo-Man R (2012) Method for preparing multi-
ple antigen glycopeptide carbohydrate conjugates. European Pat-
ent Application EP 2500 033 A1 (Applicant Institut Pasteur)
 23. Gerard C, Baudson N, Ory T, Louahed J (2014) Tumor mouse 
model confirms MAGE-A3 cancer immunotherapeutic as an effi-
cient inducer of long-lasting anti-tumoral responses. PLoS ONE 
9(5):e94883. doi:10.1371/journal.pone.0094883
 24. Allen PM, Strydom DJ, Unanue ER (1984) Processing of 
lysozyme by macrophages: identification of the determinant 
recognized by two T-cell hybridomas. Proc Natl Acad Sci USA 
81(8):2489–2493
 25. Swain SL, Dialynas DP, Fitch FW, English M (1984) Monoclo-
nal antibody to L3T4 blocks the function of T cells specific for 
class 2 major histocompatibility complex antigens. J Immunol 
132(3):1118–1123
 26. Hubert P, Heitzmann A, Viel S, Nicolas A, Sastre-Garau X, 
Oppezzo P, Pritsch O, Osinaga E, Amigorena S (2011) Antibody-
dependent cell cytotoxicity synapses form in mice during tumor-
specific antibody immunotherapy. Cancer Res 71(15):5134–
5143. doi:10.1158/0008-5472.CAN-10-4222
 27. Kruit WH, Suciu S, Dreno B, Mortier L, Robert C, Chiarion-
Sileni V, Maio M, Testori A, Dorval T, Grob JJ, Becker JC, Spatz 
A, Eggermont AM, Louahed J, Lehmann FF, Brichard VG, Keil-
holz U (2013) Selection of immunostimulant AS15 for active 
immunization with MAGE-A3 protein: results of a randomized 
phase II study of the European Organisation for Research and 
Treatment of Cancer Melanoma Group in Metastatic Melanoma. 
J Clin Oncol 31(19):2413–2420. doi:10.1200/JCO.2012.43.7111
 28. O’Sullivan D, Sidney J, Del Guercio MF, Colon SM, Sette A 
(1991) Truncation analysis of several DR binding epitopes. J 
Immunol 146(4):1240–1246
 29. James EA, Bui J, Berger D, Huston L, Roti M, Kwok WW 
(2007) Tetramer-guided epitope mapping reveals broad, indi-
vidualized repertoires of tetanus toxin-specific CD4 + T cells 
and suggests HLA-based differences in epitope recognition. Int 
Immunol 19(11):1291–1301. doi:10.1093/intimm/dxm099
 30. Lo-Man R, Vichier-Guerre S, Perraut R, Deriaud E, Huteau V, 
BenMohamed L, Diop OM, Livingston PO, Bay S, Leclerc C 
(2004) A fully synthetic therapeutic vaccine candidate target-
ing carcinoma-associated Tn carbohydrate antigen induces 
tumor-specific antibodies in nonhuman primates. Cancer Res 
64(14):4987–4994. doi:10.1158/0008-5472.CAN-04-0252
 31. Boitel B, Blank U, Mege D, Corradin G, Sidney J, Sette A, 
Acuto O (1995) Strong similarities in antigen fine specificity 
among DRB1* 1302-restricted tetanus toxin tt830-843-specific 
TCRs in spite of highly heterogeneous CDR3. J Immunol 
154(7):3245–3255
 32. Faner R, James E, Huston L, Pujol-Borrel R, Kwok WW, Juan 
M (2010) Reassessing the role of HLA-DRB3 T-cell responses: 
evidence for significant expression and complementary anti-
gen presentation. Eur J Immunol 40(1):91–102. doi:10.1002/
eji.200939225
 33. Chia R, Achilli F, Festing MF, Fisher EM (2005) The origins 
and uses of mouse outbred stocks. Nat Genet 37(11):1181–1186. 
doi:10.1038/ng1665
 34. Costagliola S, Many MC, Denef JF, Pohlenz J, Refetoff S, Vas-
sart G (2000) Genetic immunization of outbred mice with thy-
rotropin receptor cDNA provides a model of Graves’ disease. J 
Clin Invest 105(6):803–811. doi:10.1172/JCI7665
 35. Elia L, Mennuni C, Storto M, Podda S, Calvaruso F, Salucci V, 
Aurisicchio L, Scarito A, Ciliberto G, La Monica N, Palombo 
F (2006) Genetic vaccines against Ep-CAM break tolerance to 
self in a limited subset of subjects: initial identification of predic-
tive biomarkers. Eur J Immunol 36(5):1337–1349. doi:10.1002/
eji.200535514
 36. Doxiadis GG, de Vos-Rouweler AJ, de Groot N, Otting N, 
Bontrop RE (2012) DR haplotype diversity of the cynomol-
gus macaque as defined by its transcriptome. Immunogenetics 
64(1):31–37. doi:10.1007/s00251-011-0561-5
 37. Andersson G (1998) Evolution of the human HLA-DR region. 
Front Biosci 3:d739–d745
 38. Trowsdale J (1995) “Both man & bird & beast”: comparative 
organization of MHC genes. Immunogenetics 41(1):1–17
 39. Moro M, Cecconi V, Martinoli C, Dallegno E, Giabbai B, Deg-
ano M, Glaichenhaus N, Protti MP, Dellabona P, Casorati G 
(2005) Generation of functional HLA-DR*1101 tetramers recep-
tive for loading with pathogen- or tumour-derived synthetic pep-
tides. BMC Immunol 6:24. doi:10.1186/1471-2172-6-24
 40. Slierendregt BL, Otting N, Jonker M, Bontrop RE (1994) 
Gel electrophoretic analysis of rhesus macaque major histo-
compatibility complex class II DR molecules. Hum Immunol 
40(1):33–40
 41. Bontrop RE, Otting N, de Groot NG, Doxiadis GG (1999) Major 
histocompatibility complex class II polymorphisms in primates. 
Immunol Rev 167:339–350
 42. Khazand M, Peiberg C, Nagy M, Sauermann U (1999) Mhc-DQ-
DRB haplotype analysis in the rhesus macaque: evidence for a 
number of different haplotypes displaying a low allelic polymor-
phism. Tissue Antigens 54(6):615–624
 43. Doxiadis GG, Rouweler AJ, de Groot NG, Louwerse A, 
Otting N, Verschoor EJ, Bontrop RE (2006) Extensive shar-
ing of MHC class II alleles between rhesus and cynomol-
gus macaques. Immunogenetics 58(4):259–268. doi:10.1007/
s00251-006-0083-8
 44. Doxiadis GG, de Groot N, de Groot NG, Rotmans G, de Vos-
Rouweler AJ, Bontrop RE (2010) Extensive DRB region 
diversity in cynomolgus macaques: recombination as a driv-
ing force. Immunogenetics 62(3):137–147. doi:10.1007/
s00251-010-0422-7
 45. Morita N, Yajima Y, Asanuma H, Nakada H, Fujita-Yamaguchi 
Y (2009) Inhibition of cancer cell growth by anti-Tn monoclonal 
antibody MLS128. Biosci Trends 3(1):32–37
